BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

16 articles for JP Jewell

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.EBI
Merck
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.EBI
Merck
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.EBI
Merck Research Laboratories
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.EBI
Merck Research Laboratories
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityEBI
TBA
Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.EBI
Merck Research Laboratories
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.EBI
Merck Research Laboratories
Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.EBI
Merck Research Laboratories
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.EBI
TBA
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.EBI
Merck Research Laboratories
3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitorsBDB
Bayer Aktiengesellschaft
BICYCLIC PHENOL COMPOUNDS AND USE THEREOFBDB
Medshine Discovery
Five membered-aminoheterocycle and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failureBDB
Bristol-Myers Squibb
Heterocyclic compounds and uses thereofBDB
Incyte
Pyrimidine derivativeBDB
Aska Pharmaceutical
Tetrahydrothienopyridylbutyl-tetrahydrobenzindoles: new selective ligands of the 5-HT(7) receptor.BDB
Meiji Seika Kaisha